Report
Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.
North America Blood Transfusion Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Instruments & Kits and Reagents), Application (Blood Grouping and Disease Screening), and End User (Hospitals, Diagnostic Laboratories, Blood Banks, and Plasma Fractionation Companies)
- Report Code : BMIRE00027389
- Pages : 128
The North America blood transfusion diagnostics market is expected to grow from US$ 1,815.82 million in 2022 to US$ 2,742.80 million by 2028. It is estimated to grow at a CAGR of 7.1% from 2022 to 2028.
Need for Blood Transfusion due to Rise in Organ Transplants Surgeries Drives Market Growth
Organ transplantation is a surgical procedure performed in case of failure of organs such as heart, liver, and kidney. The rising cases of chronic diseases, such as chronic kidney disease (CKD), polycystic kidney disease, cystic fibrosis, and congenital heart disease, are triggering the number of organ transplant surgeries performed. These procedures generally take hours, and a lot of blood is lost during the procedure, which leads to the requirement for blood transfusion. The public-private partnership, in collaboration with transplant coordinators, has significantly contributed to the improvement of organ transplants that require a constant need for blood transfusion. The number of organ transplant surgeries has surged in, both, developing and developed countries. Healthcare sectors in developing countries, which are gathering large attention as medical tourism destinations, are undergoing continuous advancements, which allows them to provide better and more modern medical treatments. The rising need for organ transplants is a key factor driving the demand for blood transfusion diagnostics across North America.
Market Overview
The North America blood transfusion diagnostics market has been segmented into the US, Canada, and Mexico; the US is the largest contributor to the market in this region. The blood transfusion diagnostics market growth in North America is attributed to the rising number of surgical procedures for chronic health conditions. Per the American National Red Cross Organization, 2022, ~29,000 units of red blood cells; ~5,000 units of platelets; and ~6.500 units of plasma are needed daily in the US. ~16 million blood components are transfused each year in the US. A car accident victim may require as many as 100 units of blood. According to data published by the American Academy of Orthopedic Surgeons in 2018, orthopedic surgeries are among the most commonly performed procedures in the world. Studies conducted by the American Academy of Orthopedic Surgeons estimated that the number of total joint replacement (TJR) procedures is likely to surge by 171% by 2030, while total knee replacement procedure count is expected to surge by 189%, reaching ~635,000 and 1.28 million, respectively. Thus, with the elevating number of patients undergoing orthopedic surgeries, the demand for blood transfusion is also rising, thereby boosting the blood transfusion diagnostic market in North America.
North America Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
North America Blood Transfusion Diagnostics Market Segmentation
The North America blood transfusion diagnostics market is segmented based on product, application, end user, and country. Based on product, the market is bifurcated into instruments & kits and reagents. The instruments & kits segment held a larger market share in 2022. on the basis of application, the North America blood transfusion diagnostics market is bifurcated into blood grouping and disease screening. The disease screening segment held a larger market share in 2022. In terms of end user, the North America blood transfusion diagnostics market is segmented into hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood banks segment dominated the market in 2022. The North America blood transfusion diagnostics market, by country, has been classified as the US, Canada, and Mexico; the US dominated the market in 2022.
Abbott; BAG Diagnostics GmbH; Bio-Rad Laboratories, Inc.; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; Grifols, S.A.; Immucor, Inc.; Ortho Clinical Diagnostics (QuidelOrtho Corporation); Quotient Limited; and Thermo Fisher Scientific Inc. are the leading companies operating in the North America blood transfusion diagnostics market.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Blood Transfusion Diagnostics Market – By Product
1.3.2 North America Blood Transfusion Diagnostics Market – By Application
1.3.3 North America Blood Transfusion Diagnostics Market – By End User
1.3.4 North America Blood Transfusion Diagnostics Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Blood Transfusion Diagnostics Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Experts Opinion
5. North America Blood Transfusion Diagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rapid Rise in Chronic Diseases
5.1.2 Growing Need for Blood Transfusion due to Rise in Organ Transplants Surgeries
5.2 Market Restraints
5.2.1 Problems associated with Blood Transfusion Services
5.3 Market Opportunities
5.3.1 Elevated Healthcare Expenditure in Emerging Economies
5.4 Future Trends
5.4.1 Technological Developments in Blood Transfusion Diagnostics
5.5 Impact Analysis
6. Blood Transfusion Diagnostics Market– North America Analysis
6.1 North America Blood Transfusion Diagnostics Market Revenue Forecast and Analysis
7. North America Blood Transfusion Diagnostics Market Analysis – By Product
7.1 Overview
7.2 North America Blood Transfusion Diagnostics Market Revenue Share, by Product (2021 and 2028)
7.3 Instruments and Kits
7.3.1 Overview
7.3.2 Instruments and Kits: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
7.4 Reagents
7.4.1 Overview
7.4.2 Reagents: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
8. North America Blood Transfusion Diagnostics Market Analysis – By Application
8.1 Overview
8.2 North America Blood Transfusion Diagnostics Market Revenue Share, by Application (2021 and 2028)
8.3 Disease Screening
8.3.1 Overview
8.3.2 Disease Screening: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
8.4 Blood Grouping
8.4.1 Overview
8.4.2 Blood Grouping: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
9. North America Blood Transfusion Diagnostics Market Analysis – By End User
9.1 Overview
9.2 North America Blood Transfusion Diagnostics Market Share, by End User, 2021 and 2028, (%)
9.3 Blood Banks
9.3.1 Overview
9.3.2 Blood Banks: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
9.4 Hospitals
9.4.1 Overview
9.4.2 Hospitals: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
9.5 Diagnostic Laboratories
9.5.1 Overview
9.5.2 Diagnostic Laboratories: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
9.6 Plasma Fractionation Companies
9.6.1 Overview
9.6.2 Plasma Fractionation Companies: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
10. North America Blood Transfusion Diagnostics Market Analysis – Country Analysis
10.1 Overview
10.1.2 North America: Blood Transfusion Diagnostics Market, by Country, 2021 & 2028 (%)
10.1.2.1 US: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.1 US: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.2 US: Blood Transfusion Diagnostics Market, by Product, 2019–2028 (USD Million)
10.1.2.1.3 US: Blood Transfusion Diagnostics Market, by Application, 2019–2028 (USD Million)
10.1.2.1.4 US: Blood Transfusion Diagnostics Market, by End User, 2019–2028 (USD Million)
10.1.2.2 Canada: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.1 Canada: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.2 Canada: Blood Transfusion Diagnostics Market, by Product, 2019–2028 (USD Million)
10.1.2.2.3 Canada: Blood Transfusion Diagnostics Market, by Application, 2019–2028 (USD Million)
10.1.2.2.4 Canada: Blood Transfusion Diagnostics Market, by End User, 2019–2028 (USD Million)
10.1.2.3 Mexico: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.1 Mexico: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.2 Mexico: Blood Transfusion Diagnostics Market, by Product, 2019–2028 (USD Million)
10.1.2.3.3 Mexico: Blood Transfusion Diagnostics Market, by Application, 2019–2028 (USD Million)
10.1.2.3.4 Mexico: Blood Transfusion Diagnostics Market, by End User, 2019–2028 (USD Million)
11. Industry Landscape
11.1 Overview
11.2 Inorganic Growth Strategies
11.2.1 Overview
11.3 Organic Growth Strategies
11.3.1 Overview
12. Company Profiles
12.1 Grifols, S.A.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Immucor, Inc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bio-Rad Laboratories, Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Abbott
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Ortho Clinical Diagnostics (QuidelOrtho Corporation)
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 DiaSorin S.p.A.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Quotient Limited
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 BAG Diagnostics GmbH
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (US$ Mn)
Table 2. US: Blood Transfusion Diagnostics Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 3. US: Blood Transfusion Diagnostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 4. US: Blood Transfusion Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 5. Canada: Blood Transfusion Diagnostics Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 6. Canada: Blood Transfusion Diagnostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada: Blood Transfusion Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 8. Mexico: Blood Transfusion Diagnostics Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 9. Mexico: Blood Transfusion Diagnostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 10. Mexico: Blood Transfusion Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 11. Recent Inorganic Growth Strategies
Table 12. Recent Organic Growth Strategies
Table 13. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Blood Transfusion Diagnostics Market Segmentation
Figure 2. North America Blood Transfusion Diagnostics Market – By Country
Figure 3. North America Blood Transfusion Diagnostics Market Overview
Figure 4. North America Blood Transfusion Diagnostics Market, By Product
Figure 5. North America Blood Transfusion Diagnostics Market, By Country
Figure 6. North America: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis: North America Blood Transfusion Diagnostics Market
Figure 9. North America Blood Transfusion Diagnostics Market– Revenue Forecast and Analysis
Figure 10. North America Blood Transfusion Diagnostics Market Revenue Share, by Product (2021 and 2028)
Figure 11. North America Instruments and Kits: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 12. North America Reagents: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 13. North America Blood Transfusion Diagnostics Market Revenue Share, by Application (2021 and 2028)
Figure 14. North America Disease Screening: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 15. North America Blood Grouping: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 16. North America Blood Transfusion Diagnostics Market Share, by End User, 2021 and 2028 (%)
Figure 17. North America Blood Banks: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
Figure 18. North America Hospitals: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 19. North America Diagnostic Laboratories: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
Figure 20. North America Plasma Fractionation Companies: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
Figure 21. North America: Blood Transfusion Diagnostics Market, by Key Country – Revenue (2021) (USD Million)
Figure 22. North America: Blood Transfusion Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 23. US: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 24. Canada: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 25. Mexico: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America blood transfusion diagnostics market.
● Highlights key business priorities to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the North America blood transfusion diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the blood transfusion diagnostics market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
The List of Companies – North America Blood Transfusion Diagnostics Market
● Abbott
● BAG Diagnostics GmbH
● Bio-Rad Laboratories, Inc.
● DiaSorin S.p.A.
● F. Hoffmann-La Roche Ltd
● Grifols, S.A.
● Immucor, Inc.
● Ortho Clinical Diagnostics (QuidelOrtho Corporation)
● Quotient Limited
● Thermo Fisher Scientific Inc.
At 7.1% CAGR, the North America Blood Transfusion Diagnostics Market is speculated to be worth US$ 2,742.80 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the North America blood transfusion diagnostics market was valued at US$ 1,815.82 million in 2022 and is expected to reach US$ 2,742.80 million by 2028, registering an annual growth rate of 7.1% from 2022 to 2028. Rapid increase in chronic diseases and need for blood transfusion due to rise in organ transplants surgeries are the critical factors attributed to the market expansion.
The population is undergoing many lifestyle changes that leading to a steady increase in the prevalence of chronic medical conditions. The constant urbanization and the rapid growth in the middle-class population have added substantially to the rise of the sedentary lifestyle among people. The modernization of facilities has reduced physical activities among people and increased stress from personal, professional, and societal factors. Some of the leading chronic diseases that require blood transfusion are anemia, certain cancers, thalassemia, hemophilia, and sickle cell disease. Chronic diseases affect public health, societies, and economies. Blood transfusion diagnostics are widely used in various surgical procedures, such as cardiac surgery and other invasive procedures. Chronic diseases, such as cancer, cardiovascular diseases, and renal disorders, are major causes of human death across the region. These conditions are generally treated via surgical procedures, which are associated with a chance of excessive blood loss. Fresh blood is infused into patients to maintain their blood levels. Blood transfusion diagnostics are used during the blood infusion or reinfusion processes. Hence, the blood transfusion diagnostics market is rising with the rapid increase in chronic diseases across the region.
On the contrary, problems associated with blood transfusion services hurdles the growth of North America blood transfusion diagnostics market.
Based on product, the North America blood transfusion diagnostics market is bifurcated into instruments & kits and reagents. The instruments & kits segment held 66.4% market share in 2022, amassing US$ 1,205.83 million. It is projected to garner US$ 1,839.65 million by 2028 to expand at 7.3% CAGR during 2022–2028. Based on application, the North America blood transfusion diagnostics market is bifurcated into blood grouping and disease screening. The disease screening segment held 61.0% market share in 2022, amassing US$ 1,107.51 million. It is projected to garner US$ 1,683.92 million by 2028 to expand at 7.2% CAGR during 2022–2028. Based on end user, the North America blood transfusion diagnostics market is segmented into hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood banks segment held 41.7% market share in 2022, amassing US$ 757.50 million. It is projected to garner US$ 1,180.63 million by 2028 to expand at 7.7% CAGR during 2022–2028. Based on country, the North America blood transfusion diagnostics market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 85.0% market share in 2022. It was assessed at US$ 1,542.86 million in 2022 and is likely to hit US$ 2,362.56 million by 2028, exhibiting a CAGR of 7.4% during the forecast period. Key players dominating the North America blood transfusion diagnostics market are Abbott; BAG Diagnostics GmbH; Bio-Rad Laboratories, Inc.; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; Grifols, S.A.; Immucor, Inc.; Ortho Clinical Diagnostics (QuidelOrtho Corporation); Quotient Limited; and Thermo Fisher Scientific Inc. among others.
In July 2022, Quotient Limited announced an agreement with InfYnity Biomarkers, an R&D firm dedicated to utilizing biomarkers for the management of infectious and immunology diseases, under which the two companies will partner to advance the safety and effectiveness of infectious disease testing by leveraging Quotient’s MosaiQ solution. In July 2021, DiaSorin S.p.A. announces it has completed the acquisition of Luminex Corporation for a price of USD 37.00 per share that corresponds to a total equity value of approximately USD 1.8 billion. Through the acquisition, DiaSorin will gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the United States.
Related Reports
- $3,000.00 – $5,000.00
